Sigyn Therapeutics™ Discloses In-Vitro Viral Pathogen Study apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Mr. Joyce discusses Sigyn Therapeutics vision for addressing life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome stating, Cytokine Storm Syndrome is a dis-regulated immune response that results in the overproduction of inflammatory cytokines that can induce organ failure and cause death. It can be triggered by a wide range of infectious conditions and is a leading cause of death related to severe COVID-19 infections. It also underlies sepsis, which is the number one cause of in-hospital deaths worldwide and an annual market opportunity that exceeds $20 billion. Mr Joyce added that: Cytokine Storm Syndrome can also be triggered by non-infectious disease conditions such as an adverse response to drug therapies including emerging cancer immunotherapies.
Medical Technology Stock Sigyn Therapeutics (OTC: $SIGY) Reports Results of Pilot Study to Address Inflammatory CytoVesicles
Sigyn Therapy™ is a Candidate to Treat Life-Threatening Inflammatory Conditions That Are Not Addressed with Drug Therapies
SAN DIEGO - January 6, 2021 (Investorideas.com Newswire) Medical Therapeutic technology stock news - Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an
in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream.